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Abstract 
Purpose: To determine the efficacy of Lycium barbarum polysaccharide (LBP) in ovarian cancer, and 
the synergistic effect when used in combination with paclitaxel/cisplatin (PXT∕DDP).  
Methods: ID-8 cells were injected subcutaneously into 5 groups of female C57BL/6 mice (5 
mice/group): control (Con), chemotherapy (CH, PTX/DDP), combination therapy 1 (co-CH1, PTX/DDP + 
50 mg/kg LBP), combination therapy 2 (co-CH2, 100 mg/kg LBP) and combination therapy 3 (co-CH3, 
150 mg/kg LBP). Tissue morphological changes were monitored by hematoxylin and eosin (H&E) 
staining. Protein and mRNA levels of Keap1, Nrf2) and heme oxygenase-1 (HemO-1) were analyzed by 
western blotting and real-time polymerase chain reaction (PCR), as applicable.  
Results: Growth rate and volume of tumors were significantly reduced in the chemotherapy and 
combination therapy groups, while organ index increased significantly in co-CH group. Morphological 
structure of tumor, liver and kidney became normal after combination therapy. Levels of alanine 
transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), uric acid (UA), 
creatinine (Cr) and blood urea nitrogen (BUN) were significantly decreased in co-CH group relative to 
CH group. Lymphocytes, monocytes (MNC), neutrophils, basophils and eosnophils were significantly 
regulated by combination therapy. In CH and co-CH1-3 groups, the mRNA and protein levels of Keap1, 
HO-1 and Nrf2 were significantly increased relative to those of control mice.  
Conclusion: LBP in combination with PXT∕DDP enhances the efficacy of the latter, and reduced its 
toxicity when used for the treatment of ovarian malignant tumor in mice, by activating Keap1/Nrf2 
pathway and promoting immunity. 
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It is generally known that ovarian cancer is a 
serious health and life threat to women. In the 
United States of America, more than 63 % of 
women with cancer of the ovaries died in 2015 
[1]. Approximately 1.5 % of women may come 
down with epithelial ovarian cancer (EOC) at one 
point or the other, a serious statistic due to the 
fact that this form of ovarian cancer ranks 
amongst the leading causes of cancer-induced 
fatalities in women [2]. Surgery and 
chemotherapy have been applied successfully in 
treating advanced cancers, although they have 
not resulted in significant increases in five-year 
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survival rate [3-5]. It is difficult for some patients 
to accept chemotherapy due to its severe 
adverse effects [4]. Therefore, in order to 
improve the quality of life of the cancer patient, it 
is crucial to evolve alternative and safer 
treatment regimens [5]. 
 
The combination of PXT and DDP has been in 
use as the first-line drugs for ovarian cancer. 
However, the combination kills both malignant 
cells and normal cells, leading to poor prognosis 
and poor quality of life for the patient [6, 
7].Obtained from the bark of yew roots, paclitaxel 
is a unique medicinal extract authorized for use 
in the control of the growth of cancer cells [7]. 
The side effects of the drug include bone marrow 
suppression, peripheral neuropathy and 
arthralgia [8]. DDP inhibits DNA synthesis and is 
a cell cycle non-specific agent for tumors. The 
main side effects associated with DDP are liver 
and kidney toxicity, and bone marrow 
suppression [9]. Therefore, DDP is not suitable 
for the treatment and good prognosis of patients. 
Consequently, it is important to explore a 
different strategy for treatment of ovarian cancer. 
The screening of medicinal plants for useful anti-
cancer agents with lesser side effects has been a 
research hotspot in various cancer research 
laboratories. 
LBP, the major active ingredient extracted from 
L. barbarum, has been found to possess anti-
tumor, immuno-regulative, hepato-protective, 
anti-oxidative and neuro-protective properties 
[10]. In in vitro and in vivo experiments, LBP 
showed synergistic immunotherapeutic effects 
with interferon-α2b on renal cell carcinoma [11]. 
In addition, it has been shown that LBP has 
significant antioxidant properties [12].  
 
Oxidative stress was intimately linked with 
cancers [15]. PTX and DDP induce oxidative 
stress [11,12]. Long-term chemotherapy causes 
oxidative damage, which reduces the levels and 
capacities of antioxidant enzymes. The resultant 
oxidative stress may decrease immunity and 
enhance adverse chemotherapy reactions [13-
15]. The Kelch-like ECH-associated protein 1 
(Keap1)/nuclear factor-erythroid-2-related factor 
2 (Nrf2) system, which is the master regulator of 
the anti-stress response, induces the activities of 
various enzymes via Nrf2-mediated 
transcriptional regulation under stress conditions 
[16]. Activation of Keap1/Nrf2 induces the 
synthesis of detoxification and antioxidant 
enzymes to protect cells and tissues. Reactive 
cysteinyl groups in Keap1 are stimulated by 
diverse signals, leading to uncoupling of Nrf2 
from the Keap1/Nrf2 conjugate [17]. Free Nrf2 
activates the transcription of its target genes [18].  
 
In this study, the efficacy of LBP in ovarian 
cancer, and its synergistic effects when used in 





Animal and tumor model 
 
Female C57BL/6 mice (6 – 8 weeks old; 20 – 22 
g) were obtained from the Laboratory Animal 
Center of 301 Hospital (Beijing, China). The 
protocol for all animal studies conformed with the 
provisions of National  Research Council for 
Animal Care [19]. Approval for the study was 
obtained from the Yancheng First People's 
Hospital (Ethical no. 14030251). ID-8 cells were 
generated from MOSEC ovarian cancer cell lines 
of C57BL/6 mice (Zhejiang Tianhang Biological 
Technology Co., Ltd, Zhejiang, China). The cells 
were maintained at 37 °C in RPMI 1640 medium 
with 5 % fetal bovine serum, insulin-transferrin-
selenium and 0.5% streptomycin, product of 
Gibco (USA), in a 5 % - CO2 atmosphere. Hair 
was removed from dorsal surfaces of the mice 
using a shaver. Thereafter, 3×106 ID-8 cells were 
injected s.c. into the left shoulder of each mice by 
a subcutaneously. The criteria for mice selection 
were appearance of round tumors and tumor 
diameter of 5–7 mm. 
 
Animal grouping and treatment 
 
Five groups of 25 mice (5 per group) injected 
with ID-8 cells were used for the study. These 
were: untreated control group (Con), which were 
injected in the cauda vein with 0.1 mL 0.9% 
normal saline (NS) once a week for four weeks; 
chemotherapy group (CH), which were injected 
in the cauda vein with 0.1 mL PTX (5 mg/kg) + 
DDP (3 mg/kg), once weekly for four weeks; and 
3 combination therapy groups, combination 
therapy 1（co-CH1; combination therapy 2 (co-
CH2) and combination therapy 3 (co-CH3), each 
of which received via the cauda vein, 0.1 mL 
PTX (5 mg/kg) + DDP (3 mg/kg) once a week for 
four weeks. In addition, the three combination 
therapy groups were intragastrically administered 
different doses of LBP (50, 100 and 150 mg/kg, 
respectively) [16]. 
 
Animal sacrifice and isolation of organs 
 
Two weeks prior to the end of the treatment, 
whole blood was collected from the retro-orbital 
plexus into 3 mL centrifuge tubes containing 
heparin, and preserved in the refrigerator at 4 oC. 
The mice were weighed every two days until the 
end of the experiment. They were sacrificed by 
cervical dislocation and quickly submerged in 
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ethanol (75 %) for 5 min. The spleen was 
excised in a sterile hood, after which the tumors, 
livers, kidneys, ovaries, spleens and thymuses 





Fixing of the tumors was done in formaldehyde 
(10 %) for a maximum of 12 h., while formalin 
(10%) was used for fixing the liver and kidney 
samples for 72 h. The tumor and organ samples 
were embedded in paraffin, sectioned, stained 
with H&E and read by two experienced 
pathologists. 
 
Liver and kidney function test 
 
Blood levels of Cr, AST, ALP, ALT, BUN and uric 
acid (UA) were analyzed in all groups using an 




Venous blood was subjected to complete blood 
count (CBC), which was performed with an 
automated analyzer MS4 (Melet Schloesing 4, 
Germany) used for in vitro diagnostic tests. The 
instrument was used to count the number and 
types blood cells. Sufficient quality control 
measures were taken on each test procedure to 




The total tissular RNA were lysed with Trizol 
reagent (Invitrogen). The RNA was determined 
spectrophotometrically using by NanoDrop 2000 
Spectrophotometer (Thermo Scientific, MA, 
USA). Reverse-transcription was performed with 
TakaRa RT kits (Dalian, China). 
 
Real-time PCR (RT-PCR) 
 
A Light Cycler (Roche) and SYBR RT-PCR kit 
(Takara) were used for quantitative real-time RT-





Liver and kidney tissue homogenates were lysed 
in RIPA buffer containing protease inhibitors. 
Protein concentration was determined in the 
supernatant by BCA assay (Pierce). The protein 
(30-50ug) was separated by 10 % SDS 
polyacrylamide gel electrophoresis PAGE gel, 
and transferred to nitrocellulose membrane 
(Millipore, Shanghai, China) for the detection of 
keap1, Nrf2 and HO-1. The blots were visualized 
by enhanced chemiluminescence (ECL, Thermo 




Data are expressed as mean ± SEM, and 
analyzed for statistically significant differences 
between control and treatment groups using one-
way analysis of variance (ANOVA) and IBM 
SPSS 19 software (SPSS Inc., Chicago, IL). P < 





Anti-tumor effects of combination of LBP with 
PTX/DDP   
 
Tumors from the different groups were arranged 
on a white sheet of paper (Plate 1). The results 
showed that tumor weight and tumor volume in 
the CH, co-CH1, co-CH2 and co-CH3 groups 
were reduced. Tumor weight and tumor volume 
in the co-CH1, co-CH2 and co-CH3 groups were 
significantly lower than those in CH group (p < 
0.05) (Figure 1a and 1b). In the CH, co-CH1, co-
CH2 and co-CH3 groups, tumor growth rate was 
significantly reduced when compared to the 
control group (p < 0.05), and was lower in the co-
CH than in the CH. The reduction due to LBP 
was in a dose-dependent manner (Figure 1c). 
The increasing order of % tumor inhibition was 
control group (0) ˂ CH group (13.17 ± 4.49%) ˂ 
co-CH1 group (32.86 ± 10.10%) ˂ co-CH2 group 
(47.44 ± 6.03%) ˂ co-CH3 group (61.36 ± 
3.98%) (Figure 1d). 
 
Effect of combined therapy on tumor and 
organ morphologies STOPPED 
 
Morphological changes of tissues are shown in 
Plate 2. In the CH group, the tumor morphology 
was better than that of untreated control group. 
However, there were more deleterious changes 
in the liver and kidney of the CH group when 
compared with the control group. In the co-CH1, 
co-CH2 and co-CH3 groups, the liver and kidney 
tissues tended towards normal architecture, with 
clearer intercellular spaces and karyopyknosis 
fragmentation. The morphology of the tissues 
became more normal in the co-CH group when 
compared with the CH group. 
 
Effect of combination of LBP and PTX/DDP 
on organ indices 
 
Liver index, kidney index and ovary index were 
significantly elevated in group CH when 
compared to untreated control group (p < 0.05, 
Figures 2 a, b and c). There was no significant 
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difference in spleen index and thymus index 
between the control group and the CH group 
(Figures 2 d and e). In the co-CH1, co-CH2 and 
co-CH3 groups, liver, kidney, ovary, spleen and 
thymus indices were significantly increased in a 
dose-dependent manner by combination therapy 
(p < 0.05). 
 
ALT, AST, ALP, BUN, Scr and UA are common 
clinical criteria for evaluating liver and kidney 
functions. Results shown in Figure 3 reveal that 
ALT, AST, ALP, BUN, Cr and UA values in the 
CH group were significantly higher than the 
corresponding values in the control group (p < 
0.05). The levels of ALT, AST, ALP, BUN, Scr 
and UA were sequentially and significantly 
reduced in the co-CH1, co-CH2, co-CH3 group, 
in a dose-dependent manner (p < 0.05). 
 
Effect of combination of LBP and PTX/DDP 
on immune response 
 
The WBC, RBC and platelet counts in the CH 
group were significantly lower than those of the 
control group (Figures 4 a-c). The ratios of 
lymphocytes to basophils were significantly 
decreased, while the ratios of monocytes to 
neutrophils were significantly increased (p < 
0.05; Figures 5 d-g). 
 
 
Figure 1: Anti-tumor effects of LBP-PTX/DDP combination. Data are mean ±SEM (n = 6) * #p < 0.05; 




Plate 2: Effect of combination of LBP and PTX/DDP on morphological changes in tumors and tissues 
(Data are mean ±SEM, n = 3) 
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Figure 2: Effect of combination of LBP and PTX/DDP on some organ indices in mice (data are mean 
± SEM, n = 6; *# p < 0.05, **##p < 0.01) 
 
 
Figure 3: LBP combined with PTX/DDP inhibit the clinical index. Data are mean ±SEM (n = 6).  * #p < 
0.05; **##p < 0.01 
 
Effect of combination of LBP and PTX/DDP 
on Keap1, Nrf2 and HO-1 levels 
 
In liver and kidney tissues, mRNAs for Nrf2, 
Keap1 and HO-1 were gradually increased in the 
control, CH, co-CH1, co-CH2 and co-CH3 groups 
(Figure 5). In the co-CH group, higher mRNAs of 
Keap1, Nrf2 and HO-1 were obtained when 
compared with values for control and CH groups 
in liver and kidney tissues (p < 0.05, Figure 5).  
 
In liver tissues, Keap1, Nrf2 and HO-1 proteins 
were up-regulated by LBP (Figures 6 a and b). A 
similar pattern was evident in kidney tissue 
(Figure 6 c and d). In liver and kidney tissues, 
Nrf2, Keap1 and HO-1 protein expressions in the 
co-CH group was significantly and dose-
dependently higher than the corresponding 
expressions in the CH group (p < 0.05, Figures 
6b and d). 
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Figure 4: Effect of combination of LBP and PTX/DDP on immune response in mice (data are mean ± 
SEM, n=6) of one typical result from three independent experiments with similar results. *, #p < 0.05; 




Figure 6: Effect of combination of LBP and PTX/DDP on mRNA levels of Keap1, Nrf2 and HO-1. Data 
are mean ± SEM (n = 3) 
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Figure 6: Effect of combination of LBP and PTX/DDP on the expressions of Nrf2, Keap1, and HO-1. 




Chemotherapy is very crucial in the treatment of 
ovarian cancer in that its effect directly decides 
the prognosis of the disease, but the adverse 
effect of drug and multi-drug resistance affect the 
therapeutic efficacy of ovarian carcinoma [4,5]. 
The choice of ovarian cancer for this 
investigation was based on the fact that ovarian 
cancer frequently responds poorly to DDP and 
Taxol, resulting in unsatisfactory treatment 
outcomes [3-6]. Therefore, the present study was 
carried out to investigate if the effect of 
chemotherapy could be enhanced by 
combination with LBP in the treatment of ovarian 
cancer. The results obtained revealed that 
combined treatment with LBP PTX/DDP 
significantly increased the observed anti-tumor 
effects and immune response, altered the 
morphology of tissues and lowered organ indices 
by activation of Keap, Nrf2 and HO-1. The tumor 
weight and volume in CH group were lower than 
in the untreated control group, and tumor growth 
was significantly inhibited by PTX/DDP in this 
group. Interestingly, the anti-tumor effect seen in 
the co-CH group was better than that seen in the 
CH. This clearly shows that combination of 
chemotherapy and LBP, given at the same time, 
can significantly reduce the growth of ovarian 
cancer. Moreover, the enhancement of effect of 
chemotherapy by LBP was dose-dependent.  
 
Serum levels of transaminases and ALP are 
recognized markers of liver damage [20], while 
kidney damage is assessed by serum levels of 
Cr, BUN, and UA [21]. In this study, although the 
shape of tumor tissues in CH group was better 
than the shape seen in the control group, more 
tissue lesions were evident in the kidney tissues 
of the CH group. In addition, serum 
transaminases, ALP, Cr, BUN, and UA were 
significantly increased in the CH group. These 
results indicate that although chemotherapy had 
a beneficial treatment effect, it brought about 
liver and kidney impairment. In the co-CH group, 
the shape of tumor, liver and kidney tissues 
improved dose-dependently, and markers of liver 
and kidney damage were down-regulated 
significantly by the combination therapy. Thus 
LBP offered protection to liver and kidney 
tissues, and enhanced the anti-tumor effect of 
PTX/DDP. The liver and kidney injury caused by 
PTX/DDP was catabatic in the co-CH group. It 
was also shown that the combination of LBP and 
PTX/DDP altered (in a positive manner) the 
morphology of tissues and decreased organ 
indices.  
 
The spleen and thymus are immune-related 
organs, which influence platelet count, red blood 
cell count and even white blood cell count. 
Indices of liver, kidney, ovary, spleen and thymus 
were decreased in the CH group, the counts of 
WBC, RBC and platelet in the CH group were 
lower than those of control group, and the 
lymphocyte ratio was decreased. In the co-CH 
group, organ indices were increased significantly 
by LBP; WBC, RBC, and platelet counts were 
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increased, and lymphocyte ratios were increased 
in a dose-dependent manner. These results 
suggest that LBP exerted a positive effect by 
reversing the damage to the injured organs.  
 
Nrf2 and Keap1 are central regulatory factors in 
anti-oxidative reactions. The detoxifying 
enzymes, glutathione synthetase and 
peroxiredoxins activated and released by the 
Keap1/Nrf2 pathway, protect cells against 
oxidative stress and maintain homeostasis [13-
15]. This study demonstrated that LBP up-
regulated the mRNA and protein levels of Keap1, 
Nrf2 and HO-1 in liver and kidney in the co-CH 
group. Heme oxygenase-1 (HO-1), as a phase 1 
detoxifying enzyme, is a downstream gene of 
Nrf2, which is essential for detoxification in the 
liver. LBP may have activated the function of 
Nrf2 so as to counteract the effects of the tumor. 
The mRNA and protein levels of Keap1, Nrf2 and 
HO-1 in liver and kidney were increased in a 
dose-dependent manner in the co-CH group. In 
all, these results indicate that LBP exerted 
antioxidant effects via activation of Keap1/Nrf2, 
thereby enhancing the capacity of immune 
response.  
 
The observed effect of LBP is considered 
important for improvement of effectiveness of 
chemotherapy. The combination of LBP with 
PTX/DDP significantly enhanced the anti-tumor 
effect and immune response, altered the 
morphology of tissues and decreased organ 





Combined treatment with LBP and PTX/DDP 
significantly enhances chemotherapy efficacy 
and reduces chemotherapy-induced toxicity by 
strengthening immune response, increased 
detoxification capability and activated Keap1/Nrf2 
pathway. These findings indicate that LBP may 
regulate immunity, and is thus a potential source 
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